News

Filter

Current filters:

ZetiaPharmaceutical

1 to 9 of 14 results

Study shows mutations in NPC1L1 protein cut coronary heart disease

Study shows mutations in NPC1L1 protein cut coronary heart disease

14-11-2014

A new study part-funded by US pharma giant Merck & Co (NYSE: MRK) has found that mutations in a gene…

Cardio-vascularCoronary heart diseaseMerck & CoPharmaceuticalResearchUnited StatesUSAZetia

Merck's revenue drops 1% but still beats analysts' estimates for 2nd-qtr

Merck's revenue drops 1% but still beats analysts' estimates for 2nd-qtr

29-07-2014

Global revenue at pharma giant Merck & Co slipped 1% but the company has still exceeded analysts’ estimates…

FinancialFinancial accountingGardasilHepatitis CIsentressMerckMerck & CoNasonexPharma giantPharmaceuticalRemicadeUSAVytorinZetia

High potency statins linked to better outcome following a heart attack

21-02-2014

A study looking at the data of thousands of patients who suffered heart attacks has suggested treatment…

Cardio-vascularezetimibeMerck & CoPharmaceuticalResearchZetia

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Merck & Co records loss in 2nd quarter as Singulair drops 80%

30-07-2013

US pharma giant Merck & Co (NYSE: MRK) has released second quarter results showing that worldwide sales…

FinancialGardasilIsentressJanumetJanuviaMerck & CoNorth AmericaPharmaceuticalRemicadeSimponi ARIASingulairVytorinZetia

Merck & Co to pay $688 million to settle investor law suits; Teva could face $2.1 billion damages

15-02-2013

US pharma giant Merck & Co (NYSE: MRK) said yesterday that it has reached an agreement in principle with…

FinancialGenericsLegalMerck & CoPharmaceuticalProtonixTeva Pharmaceutical IndustriesVytorinZetia

Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute

30-04-2012

US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion,…

FinancialLegalMerck & CoMylan LaboratoriesNorth AmericaPatentsPharmaceuticalVytorinZetia

1 to 9 of 14 results

COMPANY SPOTLIGHT

Menarini

Back to top